What is Ye Weiguo’s remaining GYRE share ownership after these transactions?

Following the reported option exercises and open-market sales, Ye Weiguo directly holds 700,000 shares of GYRE common stock. This figure reflects his position after selling 34,976 shares that were acquired through exercising stock options at an exercise price of $0.75 per share.

What details do the Form 4 footnotes provide about GYRE share sale prices?

The footnotes state the reported prices are weighted averages, with June 4 sales executed between $6.05 and $6.30 and June 5 sales between $6.15 and $6.60. Full breakdowns of shares sold at each price are available upon request to relevant parties.

GYRE COO sells 34,976 shares after option exercise

GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock. On June 4, 2026 and June 5, 2026, he exercised stock options to acquire a total of 34,976 shares of common stock at an exercise price of $0.75 per share and then sold the same number of shares in open-market transactions.

The 19,575-share sale on June 4 occurred at a weighted average price of $6.13 per share in trades ranging from $6.05 to $6.30, while the 15,401-share sale on June 5 was at a weighted average price of $6.40 per share in trades ranging from $6.15 to $6.60. After these transactions, Weiguo directly holds 700,000 shares of GYRE common stock.

Insider Trade Summary

Exercise and Sale: 34,976 shares ($192K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 34,976 shs ($219K)

Approx. gross sale proceeds $219K

Approx. exercise cost $26K

Approx. pre-tax spread $192K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,401	$0.00	$0.00
Exercise	Common Stock	15,401	$0.75	$12K
Sale	Common Stock	15,401	$6.40	$99K
Exercise	Stock Option (Right to Buy)	19,575	$0.00	$0.00
Exercise	Common Stock	19,575	$0.75	$15K
Sale	Common Stock	19,575	$6.13	$120K

Holdings After Transaction: Stock Option (Right to Buy) — 862,419 contracts (Direct); Common Stock — 700,000 shares (Direct)

Footnotes (3)

F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3. These options are vested in full.

Key Figures

Shares sold: 34,976 shares Option exercise price: $0.75/share June 4 weighted average sale price: $6.13/share +4 more

7 metrics

Shares sold 34,976 shares Open-market sales on June 4–5, 2026

Option exercise price $0.75/share Stock options exercised for 34,976 shares

June 4 weighted average sale price $6.13/share 19,575 shares sold on June 4, 2026

June 4 price range $6.05–$6.30 Multiple trades on June 4, 2026

June 5 weighted average sale price $6.40/share 15,401 shares sold on June 5, 2026

June 5 price range $6.15–$6.60 Multiple trades on June 5, 2026

Shares held after transactions 700,000 shares Direct GYRE common stock ownership after June 5, 2026

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted average sale price, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale" describes the S-code trades"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for M-code entries"

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for derivative entries"

weighted average sale price financial

"footnote: "The price reported represents the weighted average sale price per share.""

expiration date financial

"expiration_date: options expiring on 2030-10-31"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GYRE COO Ye Weiguo report in this Form 4?

Ye Weiguo reported exercising stock options for 34,976 GYRE common shares at $0.75 per share and selling the same 34,976 shares in open-market transactions on June 4–5, 2026, converting an option position into cash while retaining a sizable shareholding.

How many GYRE shares did Ye Weiguo sell and at what prices?

He sold 19,575 GYRE common shares at a weighted average price of $6.13 on June 4 and 15,401 shares at $6.40 on June 5. Footnotes note actual trade prices ranged from $6.05–$6.60 across multiple transactions.

Were the GYRE stock sales by Ye Weiguo part of an option exercise?

Yes. The Form 4 shows code M transactions where options with a $0.75 exercise price were exercised for 34,976 shares, matched by S-code open-market sales of the same number of shares, indicating an exercise-and-sell pattern rather than a standalone share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 04:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last)

(First)

(Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		M		19,575	A	$0.75	719,575	D
Common Stock	06/04/2026		S		19,575	D	$6.13⁽¹⁾	700,000	D
Common Stock	06/05/2026		M		15,401	A	$0.75	715,401	D
Common Stock	06/05/2026		S		15,401	D	$6.4⁽²⁾	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.75	06/04/2026		M			19,575	⁽³⁾	10/31/2030	Common Stock	19,575	$0	877,820	D
Stock Option (Right to Buy)	$0.75	06/05/2026		M			15,401	⁽³⁾	10/31/2030	Common Stock	15,401	$0	862,419	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These options are vested in full.

	/s/ Weiguo Ye	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR